- Home
- TAK vs MET Comparison
TAK vs MET Comparison
Compare TAK & MET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAK
- MET
- Stock Information
- Founded
- TAK 1781
- MET 1863
- Country
- TAK Japan
- MET United States
- Employees
- TAK N/A
- MET N/A
- Industry
- TAK Biotechnology: Pharmaceutical Preparations
- MET Life Insurance
- Sector
- TAK Health Care
- MET Finance
- Exchange
- TAK Nasdaq
- MET Nasdaq
- Market Cap
- TAK 47.3B
- MET 49.7B
- IPO Year
- TAK N/A
- MET N/A
- Fundamental
- Price
- TAK $15.16
- MET $80.56
- Analyst Decision
- TAK
- MET Strong Buy
- Analyst Count
- TAK 0
- MET 10
- Target Price
- TAK N/A
- MET $95.60
- AVG Volume (30 Days)
- TAK 3.1M
- MET 3.2M
- Earning Date
- TAK 10-30-2025
- MET 10-29-2025
- Dividend Yield
- TAK 3.58%
- MET 2.82%
- EPS Growth
- TAK N/A
- MET 61.27
- EPS
- TAK 0.59
- MET 5.93
- Revenue
- TAK $31,053,301,865.00
- MET $73,011,000,000.00
- Revenue This Year
- TAK $0.40
- MET $6.71
- Revenue Next Year
- TAK $0.83
- MET $3.61
- P/E Ratio
- TAK $25.64
- MET $13.59
- Revenue Growth
- TAK 1.52
- MET 6.17
- 52 Week Low
- TAK $12.80
- MET $65.21
- 52 Week High
- TAK $15.56
- MET $89.05
- Technical
- Relative Strength Index (RSI)
- TAK 57.04
- MET 58.59
- Support Level
- TAK $14.90
- MET $80.52
- Resistance Level
- TAK $15.53
- MET $81.68
- Average True Range (ATR)
- TAK 0.13
- MET 1.16
- MACD
- TAK 0.01
- MET 0.34
- Stochastic Oscillator
- TAK 53.98
- MET 75.05
About TAK Takeda Pharmaceutical Company Limited (each representing 1/2 of a share of)
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
About MET MetLife Inc.
MetLife is one of the largest life insurers in the us by assets and provides a variety of insurance and financial-services products. It is organized into five segments: us, Asia, Latin America, Europe/Middle East/Africa, and MetLife Holdings. The us business contributes around 50% of earnings and is broken into the group benefits segment and the retirement solutions segment. The Asia segment contributes around 22% of earnings and is mainly composed of the Japan business, with increasing contributions from India, China, and Bangladesh. The company also holds leading market positions in Mexico and Chile, with the Latin America segment contributing around 13% of earnings. The EMEA and MetLife Holdings segments contribute around 4% and 11% of earnings, respectively.